Glycosylation has been shown to promote tumor invasion (48), suggesting that the therapies targeting glycosylation-related metabolic pathways could be explored for LCA2. Meanwhile, the degree of metabolic pathway abnormality was significantly higher in the LCA2 group. This evidence concerns the gene RPE65 and neoplasm.